A Phase 1 Study to Investigate the Safety, Tolerance, Foo... | NCT02827513

NCT02827513

Status Module

Description Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Arm 1	Experimental	Participants will receive sustained release (SR) Tablet Formulation 1 (SR1) containing 100 mg of Centanafadine (CTN) (2 x 100 mg tablets taken orally by mouth [PO] in the morning at starting at approximately 7 am and 2 x 100 mg tablets PO 5 hours later) for a total daily dose (TTD) of 400 mg on Days 1, 4, 7, and 10.	Drug: CTN SR1
Arm 2	Experimental	Participants will receive extended release (XR) Tablet Formulation 1 (XR1) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.	Drug: CTN XR1
Arm 3	Experimental	Participants will receive XR Tablet Formulation 2 (XR2) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.	Drug: CTN XR2
Arm 4	Experimental	Participants will receive XR Tablet Formulation 3 (XR3) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.	Drug: CTN XR3

Name	Type	Description	Arm Group Labels	Other Names
CTN SR1	Drug		Arm 1	Centanafadine
CTN XR1

Outcomes Module

Measure	Description	Time Frame
Number of participants with treatment emergent adverse events and serious adverse events		Up to approximately 12 days

Secondary Outcomes

Measure	Description	Time Frame
Maximum observed plasma concentration (Cmax) of Centanafadine (CTN) and metabolite	Blood samples for the determination of plasma concentrations of CTN and metabolite will be collected following dosing as follows: For Part A- on Days 1, 4, 7, and 10 at Pre-dose, hour 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 18; Days 2, 5, 8, and 11 at hour 24, 30, and 36; Days 3, 6, 9, and 12 at hour 48. For Part B- on Day 1 at Pre-dose, hour 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, and 18; Day 2 at Hour 24/Pre-dose; Day 4 at Pre-dose; Day 5 at Pre-dose, hour 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, and 18; Day 6 at hour 24 and 36; Day 7 at hour 48. For Part C- on Days 1 and 4 at Pre-dose, hour 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 18; Days 2 and 5 at hour 24, 30, and 36; Days 3 and 6 at hour 48

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Body weight within the normal range for height (body mass index [BMI] between 19-30 kg/m2 inclusive);
Negative serum pregnancy test at Screening and negative urine pregnancy test at Day -1 for females of child bearing potential;
Women of child-bearing potential must agree to use adequate; contraception prior to study entry, for the duration of study participation, and for 90 days following completion of therapy;
Be in general good health without clinically significant medical history;
Have clinical laboratory test results that are within the laboratory reference range; or if out of range are not clinically relevant and are acceptable to the Investigator and Sponsor medical representative;
Negative Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C Screening test;
Able and willing to give written informed consent.

Exclusion Criteria:

Use of any of the following medications will exclude a participant:
- investigational compound within 30 days prior to Screening;
- antipsychotic, anxiolytic, or sedative-hypnotic medication within 30 days prior to Screening;
- any antidepressant medication within 30 days prior to Screening;
- clonidine within 30 days prior to Screening;
- cough/cold preparations containing stimulants/sympathomimetic agent within 7 days prior to Day -1;
- norepinephrine reuptake inhibitors, such as tomoxetine (STRATTERA®) within 30 days prior to Day -1;
- antihypertensive agents, including diuretics, are not permitted at any time prior to or during the study;
- sedating antihistamines (as a single preparation or in combination) within 7 days prior to Day -1;
- sympathomimetics, appetite suppressants, modafinil, methylphenidate, amphetamine and pemoline within 7 days prior to Day -1;
- Use over the counter medications within 7 days of Investigational Product administration, with the exception of simple analgesics such as paracetamol, oral non-steroidal anti-inflammatory agents and the oral contraceptive pill (if applicable);
- Use of any herbal preparations and melatonin is prohibited and should be discontinued prior to Day -1. The process for discontinuing use of herbal preparations and melatonin prior to Day -1 is at the discretion of the Investigator;
A history of, or current evidence for, suicidal ideation, based upon clinical interview and the Columbia Suicide Severity Rating Scale (C-SSRS);
A history of known or suspected seizures, spasms, infantile spasms, febrile convulsions, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits);
Subject has a known history of hypertension or Subject has a supine systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥90 mm Hg. No more than one repeat measurement will be permitted;
Subject has a known history of orthostatic hypotension or has an orthostatic blood pressure (BP) drop of ≥20 mm Hg (based on the drop between supine and standing [3 minutes] SBP) at Screening or Day -1;

Note: The eligibility criteria list is not exhaustive.

ID	Term
D019958	Attention Deficit and Disruptive Behavior Disorders
D065886	Neurodevelopmental Disorders
D001523	Mental Disorders